Clinical trial
A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In…
NCT00224497 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00224497 |
|---|---|
| Title | A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease |
| Official title | A Phase IIa/b Double-blind, Randomised, Placebo-controlled, Linear Trend Design Dose-ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | SB-742457 |
| Enrollment | 380 |
| Start date | Sep 1, 2005 |
| First posted | Sep 23, 2005 |
| Last update posted | Dec 24, 2009 |
| Countries | Austria, Bulgaria, Chile, Croatia, Czechia, Greece, New Zealand, Poland, Russia, Slovakia, South Africa, South Korea and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: